# GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage

> **NCT01298830** · PHASE1,PHASE2 · TERMINATED · sponsor: **CellMed AG, a subsidiary of BTG plc.** · enrollment: 11 (actual)

## Conditions studied

- Intracerebral Hemorrhage (ICH)

## Interventions

- **DRUG:** GLP-1 CellBeads

## Key facts

- **NCT ID:** NCT01298830
- **Lead sponsor:** CellMed AG, a subsidiary of BTG plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Need for improvement of study medication. Safety data collected sufficient. No further gain in knowledge expected.
- **Last updated:** 2013-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298830, "GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01298830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*